Rising KashmirRising KashmirRising Kashmir
  • Home
  • Top Stories
  • News
    • Kashmir
    • City
    • Jammu
    • Politics
  • Health
  • Anchor
  • Features
  • Interview
  • Video
Search

Archives

  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022

Categories

  • Anchor
  • Breaking
  • Business
  • City
  • Developing Story
  • Editorial
  • Education
  • Features
  • Health
  • Interview
  • Jammu
  • Jammu and Kashmir News
  • Kashmir
  • Kashmir Tourism
  • Kath Bath
  • National
  • Opinion
  • Politics
  • Sports
  • Technology
  • Top Stories
  • Trending
  • Uncategorized
  • Video
  • Viewpoint
  • World
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Reading: Concerns of Long Term Stomach Medications (PPIs)
Share
Notification Show More
Font ResizerAa
Rising KashmirRising Kashmir
Font ResizerAa
  • Home
  • Top Stories
  • News
  • Health
  • Anchor
  • Features
  • Interview
  • Video
Search
  • Home
  • Top Stories
  • News
    • Kashmir
    • City
    • Jammu
    • Politics
  • Health
  • Anchor
  • Features
  • Interview
  • Video
Follow US
© 2024. All Rights Reserved.
Rising Kashmir > Blog > Opinion > Concerns of Long Term Stomach Medications (PPIs)
Opinion

Concerns of Long Term Stomach Medications (PPIs)

Over the years, concerns have been raised on the safety of PPIs as they have been associated with several adverse effects

DR. WAJEED YOUSUF
Last updated: October 13, 2024 12:03 am
DR. WAJEED YOUSUF
Published: October 13, 2024
Share
7 Min Read
SHARE

Gastric acid has long been known to be a major contributing factor in various upper gastrointestinal illnesses. Nearly three decades of targeted efforts led to the launch of the first proton pump inhibitor (PPI), omeprazole, in 1988. Several other PPIs were introduced subsequently-pantoprazole, lansoprazole, esomeprazole, rabeprazole, ilaprazole and dexlansoprazole. The availability of PPI changed the landscape of management of acid-related gastrointestinal disorders.

 

Proton pump inhibitor (PPIs) was first approved for use in the year 1989.These medicines are used for acid suppression of stomach and are more potent for acid inhibition during daytime. They are effective in treating a variety of gastric acid-related disorders. They are freely available and based on current evidence, use of PPIs for inappropriate indications and duration appears to be common. Over the years, concerns have been raised on the safety of PPIs as they have been associated with several adverse effects. Hence, there is a need to promote the use of PPIs for appropriate indication and duration.

 

PPIs are the most commonly prescribed medication worldwide. It has been seen that 25-70 % of prescriptions do not have appropriate indications. One of the Indian studies shows that 91% of the prescriptions of PPIs do not have appropriate indication. Large number of affected patients are provided ongoing treatment with PPI administration for several years.

 

Accepted Indications for PPI Use

  • Erosive Esophagitis.
  • H Pylori Eradication.
  • Dyspepsia
  • Gastric Ulcer.
  • Pathologic hypersecretory conditions.
  • Critically ill patients on prolonged mechanical ventilation.
  • Functional Dyspepsia.
  • Approved indications for long term PPI use.
  • Maintenance of symptom control in GERD.
  • Maintenance of healing of erosive esophagitis.
  • Barrett’s esophagus.
  • NSAID users at increased risk (Age >70, prior ulcer, high dose NSAIDS etc.)
  • Antiplatelet agent users with increased risk.
  • Pathological hypersecretory conditions.

 

 

 

 

Disadvantages of long term PPI

  1. Allergic reaction.
  2. Gastrointestinal infections: PPIs suppress the acid secretion which can lead to growth of bacteria which are otherwise suppressed by acid environment.
  3. Pneumonia: The function of immune cells may be impaired due to PPI use and can lead to respiratory infections.
  4. Small intestinal bacterial overgrowth: As a result of alterations in the gut microbiome due to PPI use.
  5. Iron deficiency.
  6. Bone fractures.
  7. Drug interactions: The therapeutic efficacy of some drugs may be less if used along with PPIs.
  8. Kidney injury: Although not an established complication of PPI use, but, kidney injury in form of interstitial nephritis or chronic kidney disease has been reported.

 

A study done in 2021 showed that the use of proton pump inhibitors is associated with a 45% increased risk of gastric cancer compared with the use of histamine-2 receptor antagonists. Gastric cancer risk increased with cumulative duration of use, cumulative omeprazole equivalents, and time since treatment initiation.

 

Optimizing the use of PPI

There are four potential scenarios of inappropriate use of PPIs:

  • For inappropriate indication.
  • For longer than the recommended duration.
  • At a higher than the recommended dose.
  • Failure to use PPIs when it is clinically indicated.

 

Large number of studies published over last two decades have shown inappropriate use in significant number of patients. PPIs should be discontinued if there is no definite indication.

 

For prescribing PPIs, strategy of both dose tapering and abrupt discontinuation has shown similar results. The strategy, however, needs to be individualized and flexible.

  1. For patients with mild erosive esophagitis, uninvestigated gastroesophageal reflux symptoms a standard dose of PPI is recommended for a maximum of 8 weeks.
  2. For patients with non-cardiac chest pain or extraesophageal symptoms of GERD, a PPI trial of up to 8 weeks can be instituted.
  3. Patients not responding to therapeutic trial of PPIs require objective evaluation for the diagnosis of GERD.
  4. In patients with uninvestigated dyspepsia without alarm features, prolonged or continuous use of PPIs is not recommended.
  5. Standard dose of PPI prophylaxis may be introduced in patients receiving single antiplatelet(aspirin) drug in the presence of additional risk factors or in those on dual anti platelets.
  6. For patients on anticoagulation (warfarin etc.), standard dose of PPI prophylaxis is recommended if thereare additional risk factors.
  7. In patients on short term or long-term steroids, routine PPI prophylaxis is not recommended.
  8. Routine PPI prophylaxis is not recommended for all patients on NSAIDS (pain killers). Risk assessment for the GI complications needs to be made before prescribing PPIs in these patients.
  9. Use of PPIs should be discouraged in children below 1 year of age.
  10. PPIs can be used during second or third trimester of pregnancy if needed. The use of PPIs should be avoided unless there is strong indication during the first trimester.
  11. There is no need to co-prescribe PPIs routinely in patients in whom antibiotics are prescribed.

 

PPIs should be only used whenever necessary. Although very safe, PPIs can lead to various adverse events. The people need to be aware about the side effects of the PPIs if used without a prescription.

 

Additionally, the unnecessary use of PPIs increases the financial burden on the patients. In USA annual expenditure on PPIs is greater than 11 billion dollars and globally the cost is greater than 25 billion dollars per year. The best strategy to follow should be prescribing PPIs in the lowest possible dose for short term basis with appropriate indications when benefits outweigh any adverse effects.

 

(The Author is MD/DNB, Consultant Gastroenterologist and Hepatologist, Life Member Indian Society of Gastroenterology. Feedback: [email protected])

A Rendezvous with Ring-dove Nests
How students learn better?
Expressing pragmatic solidarity with the differently-abled
The child workers
G20 summit in Srinagar: A signal Kashmir is open for business

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Whatsapp Whatsapp Copy Link Print
Previous Article “Restoration of statehood is our priority”, says Farooq Abdullah
Next Article India’s Carbon Market: New Framework to Tackle Emissions and Encourage Green Practices
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Stay Connected

1MFollowersLike
262kFollowersFollow
InstagramFollow
234kSubscribersSubscribe
Google NewsFollow

Latest News

Tourism comes to grind halt in Sonamarg after Pahalgam terror attack
Kashmir
May 29, 2025
SKUAST-K to establish advanced reproductive biotechnology centre to enhance animal breeding
Kashmir
May 29, 2025
DC calls for intensified action against drug abuse at NCORD review in Gbl
Kashmir
May 29, 2025
Shikara operators continue to ignore mandatory safety protocols
City
May 29, 2025

Recent Posts

  • Tourism comes to grind halt in Sonamarg after Pahalgam terror attack
  • SKUAST-K to establish advanced reproductive biotechnology centre to enhance animal breeding
  • DC calls for intensified action against drug abuse at NCORD review in Gbl
  • Shikara operators continue to ignore mandatory safety protocols
  • IUST partners with government for building safer J&K

Recent Comments

  1. BASHIR AHMAD BHAT on Poor hotel accommodation, lack of medical facilities irk Kashmiri pilgrims in Saudi Arabia, video goes viral
  2. sree vishnu movies on Pahalgam attack shatters Kashmir’s film tourism revival
  3. SavePlus on AI and Behavioural Analytics in Gaming: Making the World of Gaming Better
  4. Parul on Govt acknowledges faulty streetlights on Narbal-Tangmarg road
  5. dr gora on Women Veterinarians and the Goal of Viksit Bharat

Contact Us

Flat No 7,Press Enclave, Srinagar, 190001
0194 2477887
9971795706
[email protected]
[email protected]

Quick Link

  • E-Paper
  • About Us
  • Contact Us

Top Categories

Stay Connected

1.06MLike
262.5kFollow
InstagramFollow
234.3kSubscribe
WhatsAppFollow
Rising KashmirRising Kashmir
Follow US
© 2025. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?